Pricing Log in Create free account

Pharvaris N.V. (PHVS) vs Arcus Biosciences, Inc. (RCUS)

Pharvaris N.V. and Arcus Biosciences, Inc. are both Biotechnology companies. Arcus Biosciences, Inc. is the larger, with a market value of $2.5B against $2.3B — 1.1× the size. Pharvaris N.V. has the higher net margin (0.00% vs −453.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Pharvaris N.V. leads on 9 and Arcus Biosciences, Inc. on 4.

Valuation

Metric PHVS RCUS Biotechnology median
P/E n/m n/m 10.26
P/S n/m 22.77 9.18
P/B 6.38 6.36 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales n/m 17.49 8.98
Earnings yield (9.30%) (20.31%) (34.89%)
Free cash flow yield (7.98%) (20.51%) (24.52%)

Profitability

Metric PHVS RCUS Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (475.00%) 0.00%
Net margin 0.00% (453.00%) 0.00%
Free cash flow margin 0.00% (465.00%) 0.00%
Return on equity (71.50%) (114.11%) (50.12%)
Return on assets (64.43%) (50.56%) (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PHVS RCUS Biotechnology median
Revenue growth (TTM) — (58.33%) 6.26%
EPS growth (last fiscal year) (25.37%) (4.78%) 29.88%
Revenue growth, 5-year CAGR — 25.93% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PHVS RCUS Biotechnology median
Debt to equity 0.00 0.28 0.00
Current ratio 11.94 3.34 4.89
Net debt to EBITDA 1.72 2.27 1.01

Dividend

Metric PHVS RCUS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PHVS RCUS Biotechnology median
Market cap 2.28b 2.51b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack